Skip to main content
Fig. 3 | Journal of Nanobiotechnology

Fig. 3

From: Potentiating humoral and cellular immunity using a novel hybrid polymer-lipid nanoparticle adjuvant for HBsAg-VLP vaccine

Fig. 3

A Schematic graph of the cellular uptake of the HBsAg antigen or the cationic HBsAg/HPLNP formulation by APCs. (Created with BioRender.com) B The percentage of FITC-positive cells after incubation with HBsAg or HBsAg/HPLNP (w/w = 1/600) formulation for 4 h by flow cytometry. C The percentage of cells positive for FITC and (D) the mean fluorescence intensity (MFI) in cells were measured by flow cytometry after incubation with HBsAg/HPLNP formulations with various HPLNP/HBsAg weight ratios ranging from 0 to 1600 at a HBsAg concentration of 1 µg mL−1 for 4 h. E Intracellular fluorescent images were obtained by confocal microscopy after incubation with HBsAg or HBsAg/HPLNP (w/w = 1/600) formulation at a HBsAg concentration of 1 µg mL−1 for 4 h (Bar = 20 μm). One-way ANOVA was used for statistical analyse

Back to article page